Glutamine antagonist JHU-083 normalizes aberrant hippocampal glutaminase activity and improves cognition in APOE4 mice

Manuscript Number: 

19-0588R2

Author(s): 
Kristen R. Hollinger, Atsushi Kamiya, Sujatha Kannan, Elizabeth S. Khoury, Kevin Liaw, Eva Prchalova, Camilo Rojas, Barbara S. Slusher, Carolyn Tallon, Ajit G. Thomas, Ying Wu, Xiaolei Zhu

Disclosures

Kristen R. Hollinger

  • Nothing to Disclose

Atsushi Kamiya

  • Nothing to Disclose

Sujatha Kannan

  • Nothing to Disclose

Elizabeth S. Khoury

  • Nothing to Disclose

Kevin Liaw

  • Nothing to Disclose

Eva Prchalova

  • Nothing to Disclose

Camilo Rojas

  • Nothing to Disclose

Barbara S. Slusher

  • Consulting Fees:
    I am a co-founder of Dracen Pharmaceuticals which has licesed the glutamine antagonist prodrug technology from JHU for clinical development. I receive a $30K annual compensation as a consultant and to serve on their scientific advisory board.
    Equity:
    Yes I have founder shares in Dracen. Dracen is a private company so the value of these shares are unknown at this point. From a %, I owe approximately 6% of the company.
    Patents/Royalties
    I am the inventor on Johns Hopkins patents and applications that have been licensed to Dracen Pharmaceuticals.
    Grants
    • Agency: 
      Dracen Pharmaceuticals Sponsored Research Agreement
      Dates: 
      2017-2019

Carolyn Tallon

  • Nothing to Disclose

Ajit G. Thomas

  • Nothing to Disclose

Ying Wu

  • Nothing to Disclose

Xiaolei Zhu

  • Nothing to Disclose